Ziopharm initiated with a Buy at Lake Street. Lake Street analyst Thomas Flaten started Ziopharm with a Buy rating and $7 price target. “By unlocking the potential of its Sleeping Beauty technology,” Ziopharm is poised to “deliver a leap forward” in the personalization of cancer therapy, Flaten tells investors in a research note. The analyst sees an opportunity for “significant value generation” with near-term clinical catalysts.
https://thefly.com/landingPageNews.php?id=2888599
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.